Jennifer Lopez, MD
Ophthalmology · Aurora
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · University Physicians Incorporated · Denver Health and Hospital Authority
Hospitals listed: Denver Health Medical Center · University of Colorado Hospital Authority. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Lopez’s office to ask if they take your plan before you enroll.
State licence records
1 licence
- Colorado DR.70212Physician · since 2023 · expires 2027-04-30ActiveNo board action on this licenceCheck it with the stateWhat they told the state about themselves
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- Ophthalmology
Education
- New York University School of Medicine2019
What else the board holds
Hospitals they may admit to
Where the clinician told their state board they may admit and treat patients.
- UCHealth University of Colorado Hospital · Aurora, CO
- USC+Lac · Los Angeles, CA
Also licensed in
States the clinician told their board they are also licensed in. Only the states we check are verified.
California
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Denver Health & Hospital AuthorityDenver, COAcute Care Hospital · Government - State · Has an emergency department · Birthing-friendlyPart of Denver Health and Hospital AuthorityPatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.359, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.212, Oct 2024 – Sep 2025
- University of Colorado Hospital AuthorityAurora, COAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of University of Colorado Health, which runs 12 hospitals in 2 statesHome of University of Colorado Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.33 (1.15 to 1.52), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.19 (2.14 to 4.24) · 2,906 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.54 (1.12 to 1.96) · 10,774 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.492, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.566, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.279, Oct 2024 – Sep 2025Better than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 9 (7.8 to 10.5) · 1,332 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Denver Health & Hospital Authority
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 7 the same, 1 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.359 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.212 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.55 (0.49 to 2.61) · 279 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.16 (0.76 to 1.56) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 169.32 (110.51 to 228.13) · 44 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 36 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.2 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.3 · 59 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 75 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 1,552 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 1,688 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.47) · 1,601 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.68 (1.3 to 6.06) · 453 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.09 (0.38 to 3.8) · 85 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.37 (0.73 to 4) · 413 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 14.09 (5.28 to 22.89) · 80 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.62 (1.49 to 9.76) · 84 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.04 (0.54 to 3.55) · 63 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0 to 1.49) · 1,371 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.751 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.648 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.951 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.9 · 62 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.3 · 237 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -35 · 52 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 79.8 · 71 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.1 · 265 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.2 to 7.9) · 26 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.6 (8.1 to 16.8) · 26 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19 · 145 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.4 to 17.3) · 205 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 62 cases | No different | Jan 2024 – Dec 2024 |
What patients said (3,092 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 56% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for University of Colorado Hospital Authority
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 4 the same, 1 worse of 8 measures. Readmissions: 1 better, 10 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.33 (1.15 to 1.52) | Worse | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 3.19 (2.14 to 4.24) · 2,906 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.54 (1.12 to 1.96) · 10,774 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.492 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.566 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.279 | Better | Oct 2024 – Sep 2025 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9 (7.8 to 10.5) · 1,332 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.28 (0.58 to 1.98) · 3,487 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 175.29 (144.06 to 206.51) · 400 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 79 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.6 · 136 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 110 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.9 · 317 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.8 · 449 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 366 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.4 · 5,078 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.27 (0.09 to 0.44) · 11,709 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.05 to 0.39) · 13,154 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.43 (2.12 to 4.74) · 5,027 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.29 (1.25 to 3.33) · 4,375 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.4 (7.01 to 13.78) · 2,655 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.8 (2.76 to 6.83) · 2,855 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.57 (0.34 to 2.79) · 1,608 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.7 · 88 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.59 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.29 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.896 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 199 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 17.1 · 530 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 5.9 · 113 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -12.2 · 364 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 11.1 · 461 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17 · 655 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.7 to 6.9) · 1,332 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.8 · 85 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.1 · 97 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.1 · 277 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12 (9.5 to 15.1) · 2,456 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 1,478 cases | No different | Jan 2024 – Dec 2024 |
What patients said (5,233 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$29,588
Medicare paid this office $29,588 for 206 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection of drug into eye | 55 | $7,327 | $68 |
| Imaging of retina | 138 | $3,795 | $17 |
| Short return visit (20+ min) | 41 | $2,375 | $47 |
| Established patient complete exam of visual system | 32 | $2,299 | $56 |
| Return visit (30+ min) | 37 | $1,764 | $45 |
See all 7 services
| Injection of drug into eye | 55 | $7,327 | $68 |
| Imaging of retina | 138 | $3,795 | $17 |
| Short return visit (20+ min) | 41 | $2,375 | $47 |
| Established patient complete exam of visual system | 32 | $2,299 | $56 |
| Return visit (30+ min) | 37 | $1,764 | $45 |
| Established patient problem focused exam of visual system | 28 | $1,455 | $39 |
| Photography of the retina | 16 | $314 | $16 |
Who their Medicare patients are
206 Original Medicare patients in 2024. Average age 72 · Under 65 15% · 85 and older 12% · Women 55% · Also on Medicaid 44% · Health risk score 2.00. Sicker patients than 9 in 10 peers; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 50% · Chronic kidney disease 32% · Coronary heart disease 27% · Depression 24% · Heart failure 19% · COPD 14% · Cancer 12% · Atrial fibrillation 11% · Stroke 9%.
The office billed $269,352, Medicare allowed $40,925 and paid $29,588; for 591 services of 29 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 206 | 591 | 72 | 2.00 | $269,352 | $29,588 |
| 2023 | 79 | 197 | 72 | 1.39 | $111,212 | $13,439 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Return visit (30+ min) | 20 | $1,928 | $77 |
| Injection of drug into eye | 21 | $1,681 | $73 |
| New patient visit (45+ min) | 13 | $1,368 | $105 |
| Imaging of retina | 48 | $1,073 | $19 |
Medicaid work
$114,928 in 2024
Medicaid paid $114,928 for 2,233 billed services this clinician did in 2024, up to 71 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravitreal injection of a pharmacologic agent (separate procedure) | 480 | $39,633 |
| Injection, bevacizumab, 10 mg | 84 | $36,339 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 1,038 | $17,134 |
| Short return visit (20+ min) | 394 | $12,683 |
| Aflibercept injection | 29 | $6,582 |
| Short return visit | 190 | $1,569 |
| Return visit (30+ min) | 18 | $989 |
| 2024 | 2,233 | 7 | 71 | $114,928 |
| 2023 | 137 | 3 | 31 | $1,670 |
See the largest Medicaid services in earlier years
2023
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 103 | $1,229 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 15 | $290 |
| Short return visit | 19 | $151 |
Drugs they prescribed that Part D paid
$14,139
Pharmacies billed $14,139 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 225) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
137 generic and 88 brand-name prescriptions · $14,139 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 63 | $3,008 | $48 |
| Moxifloxacin | 48 | $1,049 | $22 |
| Dorzolamide-Timolol | 18 | $240 | $13 |
| Neomycin-Polymyxin-Dexameth | 18 | $204 | $11 |
| Latanoprost | 20 | $180 | $9 |
Year by year
| 2024 | 225 | 98 | 0% (0) | 39% | $14,139 |
| 2023 | 253 | 92 | None | 38% | $14,763 |
| 2022 | 205 | 47 | 0% (0) | 37% | $12,305 |
| 2021 | 150 | 35 | 0% (0) | 22% | $10,686 |
| 2020 | 20 | None | 0% (0) | None | $1,456 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Prednisolone Acetate | 56 | $2,652 | $47 |
| Brimonidine | 13 | $1,716 | $132 |
| Moxifloxacin | 30 | $1,028 | $34 |
| Dorzolamide-Timolol | 27 | $709 | $26 |
| Latanoprost | 49 | $669 | $14 |
| Ketorolac Tromethamine | 19 | $468 | $25 |
| Ofloxacin | 14 | $227 | $16 |
2022: 4 drugs
| Dorzolamide-Timolol | 36 | $2,299 | $64 |
| Brimonidine | 22 | $1,323 | $60 |
| Latanoprost | 64 | $704 | $11 |
| Prednisolone Acetate | 17 | $607 | $36 |
2021: 4 drugs
| Dorzolamide-Timolol | 34 | $2,223 | $65 |
| Latanoprost | 50 | $999 | $20 |
| Brimonidine | 23 | $635 | $28 |
| Timolol Maleate | 12 | $83 | $7 |
Money from drug and device companies
$216 in 2025
| 2025 | 4 | 5 | None | $216 |
| 2024 | 5 | 7 | None | $330 |
| 2023 | 6 | 11 | None | $1,953 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Healthcare Solutions | Eylea Hd | $119 | 1 payment
|
| Genentech USA | Vabysmo | $59 | 2 payments
|
| Dutch Ophthalmic USA | Eva, Combined Machine | $24 | 1 payment
|
| Biotronik Nro | Prospera | $14 | 1 payment
|
See all 5 published payments
| Biotronik Nro | Meals · 2025-09-22 | Prospera | $14 |
| Regeneron Healthcare Solutions | Meals · 2025-05-29 | Eylea Hd | $119 |
| Genentech USA | Meals · 2025-04-30 | Vabysmo | $33 |
| Dutch Ophthalmic USA | Meals · 2025-04-27 | Eva, Combined Machine | $24 |
| Genentech USA | Meals · 2025-02-12 | Susvimo | $26 |
See earlier years (2024, 2023)
2024: $330
| Astellas Pharma US | Izervay | $160 | 1 payment
|
| Genentech | Vabysmo | $85 | 3 payments
|
| Genentech USA | Vabysmo | $30 | 1 payment
|
| Abbvie | Ozurdex | $30 | 1 payment
|
| Gilead Sciences | None | $25 | 1 payment
|
2023: $1,953
| Alcon Vision | Hydrus Microstent | $1,395 | 6 payments
|
| Carl Zeiss Meditec USA | Artevo 800 | $220 | 1 payment
|
| Alimera Sciences | Iluvien | $144 | 1 payment
|
| Glaukos | None | $140 | 1 payment
|
| Abbvie | Ozurdex | $32 | 1 payment
|
| Genentech | Vabysmo | $22 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 97.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1285194761
- Licence
- CO DR.0070212Colorado DR.70212: Active
- Trained
- New York University School of Medicine, 2019
- Group
- University Physicians Incorporated · Denver Health and Hospital Authority
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207WX0107X (207WX0107X)
- Mailing address
- Po Box 110429, Aurora, CO, 80042
- NPI first listed
- 2019-03-21
- NPI last updated
- 2025-02-11
- NPI record certified
- 2025-02-11
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1675 Aurora Ct, Aurora, CO, 80045 · 777 Bannock St, Denver, CO, 80204